Carregant...

Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies

This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Intern Med
Autors principals: Cole, Ashley L., Sanoff, Hanna K., Dusetzina, Stacie B.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5820701/
https://ncbi.nlm.nih.gov/pubmed/28892541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2017.2788
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!